Application experience of extracorporeal photopheresis for treatment of acute “graft-versus-host” disease after allogeneic hematopoietic stem cell transplantation

Extracorporeal photopheresis (ECP) has been used as a component of combined immunosuppressive therapy in 53 patients with steroid-refractory
acute “graft-versus-host” disease. Overall response was observed in 35 patients (66 %; 95 % CI 52.6–77.3): complete response (CR) in 15 pts (28.3 %; 95 % CI 18–41.6) and partial response (PR) in 20 pts (37.7 %; 95 % CI 25.9–51.2). 3-year OS was 39 % in patients with clinical response (CR or PR); in the absence of clinical response OS was 8 % during the first year (p < 0.0001). Median methylprednisolone dose before ECP was 2 mg/kg/day, and at the end of ECP course – 0.7 mg/kg/day (p < 0.0001).

1. Зубаровская Л.С., Фрегатова Л.М., Афанасьев Б.В. Трансплантация гемопоэтических стволовых клеток при гемобластозах. В кн.: Клиническая онкогематология под ред. проф. М.А. Волковой, 2-е издание. М., 2007.

2. Станкевич Ю.А. Профилактика острой реакции «трансплантат против хозяина» у пациентов после аллогенной трансплантации гемопоэтических стволовых клеток. Автореф. дис. … канд. мед. наук. СПб., 2011.

3. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th edition. Edited by F.R. Appelbaum, S.J. Forman, R.S. Negrin et al. © 2004 Blackwell Publishing Ltd. UK. ISBN: 978-1-405-15348-5.

4. Shaughnessy P.J., Bolwell B.J., van Besien K. et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic ematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:1068–76.

5. McKenna K.E., Whittaker S., Rhodes L.E. et al. Evidence-based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and the U.K. Br J Dermatol 2006;154(1):7-20.

6. Dignan F.L., Greenblatt D., Cox M. et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012;47(6):824–30.

7. Messina C., Locatelli F., Lanino E. et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122:118–27.

8. Perfetti P., Carlier P., Strada P. et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008;42:609–17.

9. Greinix H.T., Knobler R.M., Worel N. et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91:405–8.

10. Greinix H.T., Socie G., Bacigalupo A. et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006;38:265–73.

11. Hackstein H., Misterek J., Nockher A. et al. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications. Transfusion 2009;49(11):2366–73.

12. Perotti C., Del Fante C., Tinelli C. et al. Extracorporeal photochemotherapy in graftversus- host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010;50(6):1359–69.

13. Westin J. R., Saliba R.M., De Lima M. et al. Steroid-refractory acute GVHD: Predictors and outcomes. Adv Hematol 2011;2011:601953.

14. Jagasia M., Arora M., Flowers M.E. et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119(1):296–307.

15. Marshall S.R. Technology Insight: ECP for the treatment of GvHD – can we offer selective immune control without generalized immunosuppression? Nature Clinical Practice Oncology 2006;3(6):302–14.

16. Greinix H.T. The Role of Extracorporeal Photopheresis in Graft-vs-Host Disease. APJOH 2009;1(3):12–6.